Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?
Publication date: 9 December 2026 Source: European Journal of Cancer, Volume 249 Author(s): Patrick Neven, Francois Duhoux, Philippe Aftimos, Patrick Berteloot, Evandro de Azambuja, Cleo De Backer, Debbie Debaere, Françoise Derouane, Christel Fontaine, Sileny Han, Greet Huygh, Michail Ignatiadis, Eline Naert, Kevin Punie, Annelies Requilé, Christos Sotiriou, Wiebren Tjalma, Koen Traen, Yannick Van Herck, Hans Wildiers
Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. // European Journal of Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S095980492601590X?dgcid=rss_sd_all
Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?. European Journal of Cancer. https://www.sciencedirect.com/science/article/pii/S095980492601590X?dgcid=rss_sd_all
“Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?.” European Journal of Cancer.
@article{article44921,
title = {Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?},
journal = {European Journal of Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S095980492601590X?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment